Arena Pharmaceuticals Inc.
www.arenapharm.com
Latest From Arena Pharmaceuticals Inc.
On A Roll: Arena Continues Streak Of Positive Data With Small Crohn's Pain Study
Arena announced encouraging data from a small Phase IIa study for olorinab (APD371) in abdominal pain associated with Crohn's disease as the company continues a streak of good news after two of its more advanced clinical-stage programs posted positive results.
CAMELLIA Adds To Belviq’s CV Confidence But ‘Caution’ Still Needed
Full results from a large cardiovascular outcomes study with Belviq show the Eisai/Arena obesity drug was not associated with higher such risk versus placebo, but neither did it show benefits in reducing major CV events, leaving uncertainty over its increased uptake amid lingering issues around diabetes and valvulopathy risks.
Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test
The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.
Deal Watch Asia Focus: Merck Partners With Alibaba For Entry To Digital Health In China
China’s Everest licenses global rights to Novartis FGFR4 inhibitor, while Altogen and Lynkogen partner in NASH and metabolic disease.
Company Information
- Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Cardiovascular
- Gastrointestinal
- Immune Disorders
- Metabolic Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Arena Pharmaceuticals Inc.
- Senior Management
-
Amit Munshi, Pres. & CEO
Kevin R Lind, EVP, CFO
Vince Aurentz, EVP, CBO
Preston Klassen, MD, EVP, R&D & CMO - Contact Info
-
Arena Pharmaceuticals Inc.
Phone: (858) 453-7200
6154 Nancy Ridge Dr.
San Diego, CA 92121
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice